Clinical trial
Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or…
NCT00331409 · OHSU Knight Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00331409 |
|---|---|
| Title | Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | A Phase II Study of the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination With Imatinib Mesylate in Patients With Previously Treated Advanced Renal Carcinoma |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | Everolimus, imatinib mesylate |
| Enrollment | 23 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | May 31, 2006 |
| Last update posted | Oct 26, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: